Is ACRS or ACTU more undervalued in 2026?

CirclFi compares Aclaris Therapeutics, Inc. (ACRS) and Actuate Therapeutics, Inc. (ACTU) using 13 institutional-grade valuation models. ACRS has a Quality of Company score of 7.1/10 while ACTU scores 3.7/10.

Which is a better buy — ACRS or ACTU?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ACRS and ACTU valuations compare?

ACRS at $4.57 and ACTU at $2.08 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ACRS vs ACTU Valuation Comparison 2026 — Intrinsic Value Analysis

ACRS

Biotechnology

Aclaris Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

LOW

Price

$4.57

Last close

Models

11/13

Active

ACTU

Biotechnology

Actuate Therapeutics, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$2.08

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	ACRS Fair Value	ACRS Upside	ACTU Fair Value	ACTU Upside
Bayesian DCF	Intrinsic	$1.33	-70.8%	$0.74	-64.6%
Earnings Power Value	Intrinsic	$0.29	-93.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.19	-74.0%	$0.85	-59.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACRS vs ACTU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACRS vs ACTU — Which Stock Is More Undervalued?

ACRS scores higher with a 7.1/10 quality rating vs ACTU's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aclaris Therapeutics, Inc. (ACRS) and Actuate Therapeutics, Inc. (ACTU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACRS currently trades at $4.57 with a QOC of 7.1/10, while ACTU trades at $2.08 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).